HER2-positive cancer companion diagnostic - Ventana

Drug Profile

HER2-positive cancer companion diagnostic - Ventana

Alternative Names: Pertuzumab companion diagnostic - Ventana; Trastuzumab companion diagnostic - Ventana; Trastuzumab emtansine companion diagnostic - Ventana; Ventana HER2 (4B5) IHC companion diagnostic assay; Ventana HER2/neu (4B5) Rabbit Monoclonal Primary Antibody Assay

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Ventana Medical Systems
  • Class Antibody diagnostics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Breast cancer
  • No development reported Gastric cancer

Most Recent Events

  • 13 Apr 2016 No recent reports on development identified - Registered for Breast cancer (Diagnosis) in USA (unspecified route)
  • 13 Apr 2016 No recent reports on development identified - Registered for Gastric cancer (Diagnosis) in USA (unspecified route)
  • 13 Dec 2013 Clinical trials in Breast cancer (diagnosis) in European Union, Canada, Japan and Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top